Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献

{"title":"Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study","authors":"Mahmoud Nassar MD, PhD, MSc, MHA, MPA, CPHQ, SSBB ,&nbsp;Omar Nassar ,&nbsp;Hazem Abosheaishaa ,&nbsp;Anoop Misra","doi":"10.1016/j.dsx.2024.103116","DOIUrl":"10.1016/j.dsx.2024.103116","url":null,"abstract":"<div><h3>Background</h3><div>Acute pancreatitis (AP) is a significant health concern with potential for recurrent episodes and serious complications. The risk of recurrence in type 2 diabetes (T2D) or obesity can be influenced by various factors and treatments, including GLP-1 receptor agonists (GLP-1RAs). This study evaluates the risk of recurrent AP among patients with a history of the condition, focusing on the effects of different GLP-1RA treatments.</div></div><div><h3>Objectives</h3><div>Our objective is to compare the recurrence risks of AP between patients treated with different GLP-1RAs.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study using the TriNetX platform, encompassing 258,238 individuals with T2D or obesity who have a history of AP. We assessed the recurrence of AP over a five-year period, analyzing data on treatment regimens, with a focus on the use of Semaglutide, Tirzepatide, and other GLP-1RAs.</div></div><div><h3>Results</h3><div>GLP-1RA users experienced significantly lower recurrence rates of AP, with those without risk factors showing GLP-1RA users had a recurrence rate of 13.8 % compared to 40.9 % for non-users. Semaglutide and Tirzepatide showed the most favorable outcomes; Semaglutide users had lower recurrence rates than Exenatide (10.1 % vs. 27 %) and slightly lower than Dulaglutide (13.6 % vs. 15.4 %), though not statistically significant with Dulaglutide. Tirzepatide users displayed the lowest recurrence risk at 6.2 %, significantly lower than those on Semaglutide (11.7 %).</div></div><div><h3>Conclusions</h3><div>GLP-1RAs, particularly Semaglutide and Tirzepatide, are associated with a reduced risk of recurrent AP in people with T2D or obesity. The differential risk profile between these drugs highlights the need for further studies and personalized treatment plans.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103116"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142322273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of the current issue","authors":"Ningjian Wang (Associate Editor) ,&nbsp;Anoop Misra (Editor-in-Chief)","doi":"10.1016/j.dsx.2024.103141","DOIUrl":"10.1016/j.dsx.2024.103141","url":null,"abstract":"","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103141"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142552819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific dietary patterns and their association with metabolic syndrome: Insights from a cross-sectional analysis","authors":"Mónica Lavinia Popescu ,&nbsp;María Rubín-García ,&nbsp;Laura Álvarez-Álvarez ,&nbsp;Estefanía Toledo ,&nbsp;Dolores Corella ,&nbsp;Jordi Salas-Salvadó ,&nbsp;Karla Alejandra Pérez-Vega ,&nbsp;J Alfredo Martínez ,&nbsp;Ángel M. Alonso-Gómez ,&nbsp;Julia Wärnberg ,&nbsp;Jesús Vioque ,&nbsp;Dora Romaguera ,&nbsp;José López-Miranda ,&nbsp;Ramón Estruch ,&nbsp;Francisco J. Tinahones ,&nbsp;José Lapetra ,&nbsp;Luís Serra-Majem ,&nbsp;Naomi Cano-Ibáñez ,&nbsp;Josep A. Tur ,&nbsp;Roi Naveiro ,&nbsp;Tania Fernández-Villa","doi":"10.1016/j.dsx.2024.103123","DOIUrl":"10.1016/j.dsx.2024.103123","url":null,"abstract":"<div><h3>Aims</h3><div>This study aims to identify <em>a posteriori</em> dietary patterns with a sex approach and to evaluate their association with metabolic syndrome criteria.</div></div><div><h3>Methods</h3><div>Cross-sectional study conducted in 6821 men and women between 55 and 75 years of age. Forty-two food groups were analyzed from dietary information collected with food frequency questionnaires, using principal component analysis and cluster analysis and then information from both statistical methods was compared. Prevalences were calculated foreach cluster group, based on the number and types of metabolic syndrome criteria they met.</div></div><div><h3>Results</h3><div>Following principal component analysis, two dietary patterns labeled “healthy” and “unhealthy” were identified in both men and women, due to the presence of foods that are considered more or less healthy. These same dietary patterns were found in cluster analysis plus an “intermediate” cluster consisting of both healthy and unhealthy foods. The presence of metabolic syndrome is related to the “healthy” dietary pattern in women and to the “unhealthy” dietary pattern in men. Comparison of the two statistical approaches showed a high level of correlation between them (weighted Kappa = 0.703 in women and weighted Kappa = 0.691 in men).</div></div><div><h3>Conclusions</h3><div>Adherence to both healthy and unhealthy dietary pattern appears to be related to the development of MS. The differences found by sex make it necessary to develop interventions with a sex-specific approach.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103123"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding obesity among young adults in India: A focus group study","authors":"Wareesha Anwar ,&nbsp;Piyush Ranjan ,&nbsp;Anita Malhotra ,&nbsp;Nikita Madan ,&nbsp;Archana Kumari ,&nbsp;Amandeep Singh ,&nbsp;Bindu Prakash ,&nbsp;Ranveer Singh Jadon ,&nbsp;Upendra Baitha ,&nbsp;Naval K. Vikram","doi":"10.1016/j.dsx.2024.103121","DOIUrl":"10.1016/j.dsx.2024.103121","url":null,"abstract":"<div><h3>Introduction</h3><div>The study aims to understand the knowledge and awareness about risk factors and consequences of obesity, barriers and motivators to weight loss, and potential solutions for weight management among young adults (YAs) in India.</div></div><div><h3>Method</h3><div>Six focus group discussions were conducted with an inductive approach among obese YAs (18–30 years) recruited through snowball and purposive sampling. The principle of maximum diversity was used to build a pool of varied and extensive information regarding obesity in YAs. The discussions were audio-recorded and transcribed verbatim using NVivo 1.0 by QSR International to generate codes, subthemes, and themes from the discussions.</div></div><div><h3>Result</h3><div>Among the thirty recruited YAs (mean age 24.7 ± 2.84 years), nearly half were from a high-income group (56.6 %) and had postgraduate education (53.3 %). Key themes included the need for increased awareness about obesity risk factors and consequences across different societal levels. Physical appearance was the primary motivator for weight loss, followed by physical endurance and social support. Major barriers included lack of energy, time, motivation, lifestyle changes, easy access to unhealthy foods, work commitments, and workplace culture. A holistic approach involving dietary changes, physical activity, and educational and policy reforms was suggested as potential solutions.</div></div><div><h3>Conclusion</h3><div>The challenges faced by YAs in developing countries regarding different aspects of the development and management of obesity are unique and different from the other population groups. Individualized weight management modules may be useful for managing obesity in this group.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103121"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of green coffee bean extract on blood pressure and heart rate: A systematic review and dose-response meta-analysis of randomized controlled trials","authors":"Simin Samavat ,&nbsp;Damoon Ashtary-Larky ,&nbsp;Fatemeh Naeini ,&nbsp;Behzad Nazarian ,&nbsp;Sara Kashkooli ,&nbsp;Cain C.T. Clark ,&nbsp;Reza Bagheri ,&nbsp;Omid Asbaghi ,&nbsp;Maryam Babaali ,&nbsp;Mohammad Ali Goudarzi ,&nbsp;Ali Zamanian ,&nbsp;Hadi Emamat","doi":"10.1016/j.dsx.2024.103120","DOIUrl":"10.1016/j.dsx.2024.103120","url":null,"abstract":"<div><h3>Background and aims</h3><div>The existing literature on the effects of green coffee bean extract (GCBE) consumption on systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) is equivocal. This study aimed to summarize the effects of GCBE consumption on SBP, DBP and HR in adults.</div></div><div><h3>Methods</h3><div>Data were pooled using a random-effects model and expressed as weighted mean difference (WMD) and 95 % confidence intervals (95 % CIs).</div></div><div><h3>Results</h3><div>Out of 1624 records, 10 studies that enrolled 563 participants were included. GCBE consumption significantly decreased SBP (WMD: −2.95 mmHg; 95 % CI: −4.27 to −1.62; p &lt; 0.001) and DBP (WMD: −2.15 mmHg; 95 % CI: −2.59 to −1.72; p &lt; 0.001). However, there was no significant effect on HR (WMD: −1.20 bpm; CI: −2.93 to 0.51; p = 0.170). Subgroup analysis showed that GCBE consumption had a more significant effect on SBP and DBP in participants with high SBP and DBP and had no effect on blood pressure in females. Linear and non-linear dose-response analyses were conducted to find the optimum GCBE dosage and duration of intervention. However, no significant associations were observed for SBP, DBP, and HR in linear meta-regression and non-linear dose-response based on the dose and duration of the intervention.</div></div><div><h3>Conclusion</h3><div>GCBE has the potential as a hypertension-reducing supplement in hypertensive patients. However, GCBE did not significantly change HR.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103120"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of peripheral arterial disease among individuals with type 2 diabetes mellitus in India - A systematic review and meta-analysis","authors":"Esha Arora ,&nbsp;Raja Regan ,&nbsp;Vyshak Uddur Surendra ,&nbsp;Ashokan Arumugam","doi":"10.1016/j.dsx.2024.103124","DOIUrl":"10.1016/j.dsx.2024.103124","url":null,"abstract":"<div><h3>Background</h3><div>Peripheral arterial disease (PAD) is a prevalent complication of type 2 diabetes mellitus (T2DM). As India ranks second in the population afflicted by T2DM, and the objective of this systematic review was to estimate the pooled prevalence of PAD in individuals living with T2DM in India.</div></div><div><h3>Methods</h3><div>Five databases (Cochrane (CENTRAL), MEDLINE (via PubMed), CINAHL (via EBSCO), PEDro, and Scopus) were searched using database-specific search terms from inception to August 2023. Inclusion criteria included studies reporting the prevalence of PAD in Indian adults diagnosed with T2DM of either or both sexes, employing ankle brachial index measurements with a Doppler test or sphygmomanometer. The risk of bias was evaluated using the JBI checklist, and the certainty of evidence was determined via the GRADE approach.</div></div><div><h3>Results</h3><div>Twenty-three articles met the inclusion criteria which comprised of 196,883 individuals with T2DM aged between 30 and 70 years from nine states and one union territory. Utilizing a random effects model, the meta-analysis revealed that the pooled prevalence of PAD among individuals with T2DM in India was 18 % (95 % confidence interval: 10–28 %), with statistically significant heterogeneity observed between studies (I² = 100 %, P &lt; 0.001). Overall certainty in the evidence was low.</div></div><div><h3>Conclusion</h3><div>The combined prevalence of PAD among individuals with T2DM in India is 18 %, indicating a significant portion of the Indian population has been affected. Epidemiological studies utilizing precise assessment tools can enhance the early detection and prevention of PAD in T2DM and improve the certainty of findings.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103124"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individual cereals intake is associated with progression of diabetes and diabetic chronic complications","authors":"Siying Tang ,&nbsp;Wenjin Luo ,&nbsp;Ting Li ,&nbsp;Xiangjun Chen ,&nbsp;Qinglian Zeng ,&nbsp;Rufei Gao ,&nbsp;Bing Kang ,&nbsp;Chuan Peng ,&nbsp;Zhihong Wang ,&nbsp;Shumin Yang ,&nbsp;Qifu Li ,&nbsp;Jinbo Hu","doi":"10.1016/j.dsx.2024.103127","DOIUrl":"10.1016/j.dsx.2024.103127","url":null,"abstract":"<div><h3>Background and aims</h3><div>The relationship between cereals intake and diabetes is unclear. We aimed to explore associations between individual cereals intake and risks of incident and progression of diabetes.</div></div><div><h3>Methods</h3><div>We included 502,490 participants from UK Biobank at baseline. A single touchscreen food frequency questionnaire was used to estimate the intake of individual cereals (bran, biscuit, oat, muesli, and other cereals). Main outcomes included incident diabetes and diabetic complications of cardiovascular disease (CVD), chronic kidney disease (CKD) and diabetic retinopathy (DR). Polygenic risk score (PRS) of glycosylated hemoglobin (HbA1c) was calculated for mediating effects analysis.</div></div><div><h3>Results</h3><div>Among participants without diabetes, when compared to subjects who never had cereals, hazard ratios (95%CI) of developing diabetes in those who had ≥6 bowls/week were 0.72 (0.67–0.78) for bran, 0.86 (0.81–0.92) for biscuit, 0.75(0.66–0.84) for oat, and 0.57(0.53,0.61) for muesli. Among people with diabetes without CVD, a higher intake of aforementioned four individual cereals was associated with a 13%–32 % lower risk of developing CVD. Among people with diabetes without CKD, a higher intake of aforementioned four individual cereals was associated with a 9%–28 % lower risk of developing CKD. We observed a significant mediating effect of the PRS of HbA1c for the association between aforementioned four individual cereals and developing diabetes.</div></div><div><h3>Conclusion</h3><div>A higher consumption of cereals was significantly associated with lower risks of diabetes and diabetic complications. Polygenic of HbA1c mediates the effect of cereals on incident diabetes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103127"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142322255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of rosuvastatin on metabolic syndrome patients with moderate to severe metabolic associated fatty liver disease without overt diabetes: A randomized clinical trial","authors":"Xuan Wang ,&nbsp;Lu Lyu ,&nbsp;Wei Li ,&nbsp;Lingling Xu ,&nbsp;Huabing Zhang ,&nbsp;Shitian Wang ,&nbsp;Yiwen Liu ,&nbsp;Fan Ping ,&nbsp;Yuxiu Li","doi":"10.1016/j.dsx.2024.103126","DOIUrl":"10.1016/j.dsx.2024.103126","url":null,"abstract":"<div><h3>Objective</h3><div>This investigation aimed to evaluate the efficacy and safety of rosuvastatin in treating moderate to severe metabolic associated fatty liver disease (MAFLD).</div></div><div><h3>Methods</h3><div>This prospective, open-label, randomized study included non-diabetic participants with metabolic syndrome and intrahepatocellular lipid (IHCL) levels &gt;10 %, as determined by proton magnetic resonance spectroscopy (¹H-MRS). The primary objective was the effect of a 52-week rosuvastatin treatment (10 mg/day) on IHCL content. Secondary objectives included the association between IHCL reduction and lipid metabolism parameters, along with safety indices such as glycemic control and hepatic and renal function<del>.</del></div></div><div><h3>Results</h3><div>Thirty-two participants completed the study. Rosuvastatin resulted in a significant absolute (△IHCL: 7.61 ± 4.51 vs. 1.54 ± 5.33, p = 0.002) and relative reduction in IHCL (△IHCL%: −42.28 ± 24.90 % vs. −8.91 ± 31.93 %, p = 0.003) compared to the control. Reduction in IHCL correlated significantly with decreases in low-density lipoprotein cholesterol (LDL-C) (r = 0.574, p &lt; 0.01), apolipoprotein B (ApoB) (r = 0.660, p &lt; 0.001), and free fatty acids (FFA) (r = 0.563, p = 0.005). No significant safety differences were observed between groups.</div></div><div><h3>Conclusions</h3><div>Rosuvastatin significantly reduced hepatic steatosis in individuals with moderate to severe MAFLD and metabolic syndrome over 52 weeks, while maintaining a favorable safety profile.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103126"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiometabolic outcomes in offspring of women treated with metformin versus insulin for gestational diabetes: A Systematic Review and meta-analysis","authors":"Dimple Rawat ,&nbsp;Yashdeep Gupta ,&nbsp;Arun Kumar Yadav ,&nbsp;Manoj Kumar Tembhre ,&nbsp;Priyanka Das ,&nbsp;Saisree Bakkireddy ,&nbsp;Neeta Singh ,&nbsp;K Aparna Sharma ,&nbsp;Rinchen Zangmo ,&nbsp;Avdhesh Chandra ,&nbsp;Ashish Datt Upadhyay ,&nbsp;Deepali Garg","doi":"10.1016/j.dsx.2024.103134","DOIUrl":"10.1016/j.dsx.2024.103134","url":null,"abstract":"<div><h3>Introduction</h3><div>Gestational diabetes mellitus (GDM) is commonly managed with either metformin or insulin, but their comparative effects on offspring cardiometabolic outcomes are not fully understood.</div></div><div><h3>Objective</h3><div>To investigate the impact of metformin and insulin, two distinct pharmacological interventions, on cardiometabolic outcomes in offspring of mothers with GDM.</div></div><div><h3>Methodology</h3><div>Systematic literature review was performed for articles (randomized control trials) published from 1974 to May 2024 using a predefined search strategy. Studies were screened for title and abstract followed by full text. Quality assessment was done using a separate risk of bias tool in line with the PRISMA-2020 checklist.</div></div><div><h3>Results</h3><div>Among 5463 records, five studies (metformin = 409 children or insulin n = 434 children) were included. Offspring of metformin-treated mothers in the age range of 5–9 years had more fat-free mass (kg) by bioimpedance and abdominal (subcutaneous and visceral) fat volume (cm³) by MRI. Fasting plasma glucose and triglycerides were lower in the metformin-treated group for offspring aged 5–9 years. No significant differences were observed for other cardiometabolic outcomes. Limited data available for offsprings less than 5 years of age precluded meta-analysis for the available outcomes, except for body weight, and difference for this was also not significant.</div></div><div><h3>Conclusion</h3><div>In short term no major differences has been seen in most of the cardiometabolic outcomes evaluated in the meta-analysis. Future trials with longer follow up are required and in different ethnicities.</div></div><div><h3>Systematic review registration</h3><div>PROSPERO-CRD42023450990.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103134"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142422737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning and statistical models to predict all-cause mortality in type 2 diabetes: Results from the UK Biobank study","authors":"Tingjing Zhang ,&nbsp;Mingyu Huang ,&nbsp;Liangkai Chen ,&nbsp;Yang Xia ,&nbsp;Weiqing Min ,&nbsp;Shuqiang Jiang","doi":"10.1016/j.dsx.2024.103135","DOIUrl":"10.1016/j.dsx.2024.103135","url":null,"abstract":"<div><h3>Aims</h3><div>This study aims to compare the performance of contemporary machine learning models with statistical models in predicting all-cause mortality in patients with type 2 diabetes mellitus and to develop a user-friendly mortality risk prediction tool.</div></div><div><h3>Methods</h3><div>A prospective cohort study was conducted including 22,579 people with diabetes from the UK Biobank. Models evaluated include Cox proportional hazards, random survival forests (RSF), gradient boosting (GB) survival, DeepSurv, and DeepHit.</div></div><div><h3>Results</h3><div>Over a median follow-up period of 9 years, 2,665 patients died. Machine learning models outperformed the Cox model in the validation dataset, with C-index values of 0.72–0.73 vs. 0.71 for Cox (p &lt; 0.01). Deep learning models, particularly DeepHit, demonstrated superior calibration and achieved lower Brier scores (0.09 vs. 0.10 for Cox, p &lt; 0.05). An online prediction tool based on the DeepHit was developed for patient care: <span><span>http://123.57.42.89:6006/</span><svg><path></path></svg></span>.</div></div><div><h3>Conclusions</h3><div>Machine learning models performed better than statistical models, highlighting the potential of machine learning techniques for predicting all-cause mortality risk and facilitating personalized healthcare management for individuals with diabetes.</div></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 9","pages":"Article 103135"},"PeriodicalIF":4.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}